A Richard Green

List of Publications by Year
in descending order

30	2,542	18	28
papers	citations	h-index	g-index
		430442	500791

32	32	32	2207
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	7.1	1,091
2	A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. European Journal of Pharmacology, 2004, 500, 3-13.	1.7	170
3	Animal models of stroke: do they have value for discovering neuroprotective agents?. Trends in Pharmacological Sciences, 2003, 24, 402-408.	4.0	156
4	3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology, 2001, 154, 251-260.	1.5	136
5	Therapeutic strategies for the treatment of stroke. Drug Discovery Today, 2006, 11, 681-693.	3.2	135
6	A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, â€˜ecstasyâ€™) on dopamine neurones in mouse brain. British Journal of Pharmacology, 2001, 134, 1711-1723.	2.7	112
7	Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. , 2003, 100, 195-214.		94
8	Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. European Neuropsychopharmacology, 2013, 23, 1085-1095.	0.3	73
9	Neuropharmacology of 5-hydroxytryptamine. British Journal of Pharmacology, 2006, 147, S145-S152.	2.7	70
10	Studies on the effect of MDMA (â€˜ecstasyâ€™) on the body temperature of rats housed at different ambient room temperatures. British Journal of Pharmacology, 2005, 146, 306-312.	2.7	62
11	Effect of Repeated (â€˜Bingeâ€™) Dosing of MDMA to Rats Housed at Normal and High Temperature on Neurotoxicdamage to Cerebral 5-Ht and Dopamine Neurones. Journal of Psychopharmacology, 2004, 18, 412-416.	2.0	57
12	MDMA: On the translation from rodent to human dosing. Psychopharmacology, 2009, 204, 375-378.	1.5	50
13	Optimising in vivo pharmacology studiesâ€"Practical PKPD considerations. Journal of Pharmacological and Toxicological Methods, 2010, 61, 146-156.	0.3	48
14	Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated (â€˜bingeâ€™ ingestion) low dose of MDMA. Psychopharmacology, 2004, 173, 264-269.	1.5	46
15	Meâ€too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. British Journal of Clinical Pharmacology, 2020, 86, 2114-2122.	1.1	37
16	Current preclinical studies on neuroinflammation and changes in bloodâ€"brain barrier integrity by MDMA and methamphetamine. Neuropharmacology, 2014, 87, 125-134.	2.0	36
17	Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology, 2011, 213, 365-376.	1.5	35
18	Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. Addiction Biology, 2016, 21, 1127-1139.	1.4	33

#	Article	IF	Citations
19	The Acute Effect in Rats of 3, 4â€Methylenedioxyethamphetamine (MDEA, â€œEveâ€) on Body Temperature and Long Term Degeneration of 5â€HT Neurones in Brain: A Comparison with MDMA (â€œEcstasyâ€). Basic and Clinical Pharmacology and Toxicology, 1999, 84, 261-266.	0.0	23
20	MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press. Psychopharmacology, 2004, 173, 231-233.	1.5	17
21	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). Journal of Psychopharmacology, 2014, 28, 711-718.	2.0	13
22	Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats. Journal of Psychopharmacology, 2016, 30, 698-706.	2.0	12
23	Induction of the cell survival kinase Sgk1: A possible novel mechanism for Î±-phenyl-N-tert-butyl nitrone in experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1111-1121.	2.4	8
24	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950â€“1980). British Journal of Clinical Pharmacology, 2018, 84, 1668-1685.	1.1	7
25	An agenda for UK clinical pharmacology: From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. British Journal of Clinical Pharmacology, 2012, 73, 959-967.	1.1	6
26	How Do We Re-Engage the Pharmaceutical Industry in Research on Serotonin and Psychiatric Disorders?. ACS Chemical Neuroscience, 2013, 4, 9-12.	1.7	5
27	Examining the â€˜psychopharmacology revolutionâ€™ (1950â€“1980) through the advertising of psychoactive drugs in the <i>British Medical Journal</i>. Journal of Psychopharmacology, 2018, 32, 1056-1066.	2.0	5
28	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6. British Journal of Clinical Pharmacology, 2019, 85, 1901-1906.	1.1	3
29	Starting with serotonin. British Journal of Clinical Pharmacology, 2008, 66, 903-904.	1.1	1
30	A Brief History of Psychopharmacology. , 2020, , 1-34.		0